Reports

Ideas That Generate Results

Russian Pharma Sector Forecast to 2013

Russian Pharma Sector Forecast to 2013

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Mar, 2011| No. of Pages : 100

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 800.00
CD-ROM Mail Delivery
US$ 900.00
Hard Copy Mail Delivery
US$ 900.00
Electronic Access - Multi-User License
US$ 1200.00

1. Analyst View

2. Demographics & Healthcare Profile
     2.1 Life Expectancy
     2.2 Age Breakup
     2.3 Hospital Beds & Doctors
     2.4 Healthcare Expenditure

3. Pharmaceutical Market Forecast to 2013
     3.1 Market Size & Growth
     3.2 Comparative Analysis
     3.3 Market Segmentation by Expenditure
     3.4 Commercial Drugs Market
            3.4.1 Imported & Domestic Drugs
            3.4.2 RX & OTC Drugs
            3.4.3 Sales Structure - By ATC Groups
            3.4.4 Leading Companies
            3.4.5 Leading Drugs
            3.4.6 Price Analysis
     3.5 State Segment
            3.5.1 Drug Reimbursement Program (DLO)
                       3.5.1.1 Imported & Domestic Drugs
                       3.5.1.2 RX & OTC Drugs
                       3.5.1.3 Sales Structure - By ATC Groups
                       3.5.1.4 Leading Companies
                       3.5.1.5 Leading Drugs
          3.5.2 Hospital Segment
                     3.5.2.1 Imported & Domestic Drugs
                     3.5.2.2 Sales Structure - By ATC Groups
                     3.5.2.3 Leading Companies
                     3.5.2.4 Leading Drugs
     3.6 Parapharmaceutical Market
            3.6.1 Nutritional Supplements Market
                       3.6.1.1 Imported & Domestic Supplements
    3.7 Market by Disease Segment
           3.7.1 Cardiovascular Drugs
           3.7.2 Hepatitis C
           3.7.3 HIV Drugs
           3.7.4 High Insulin Demand
           3.7.5 Cancer Drugs

4. Clinical Trials Market Outlook

5. Industry Analysis
     5.1 Market Driving Forces
            5.1.1 Increasing Volume & Sales of Expensive Drugs
            5.1.2 Rising Expenditure on Infrastructure Development
            5.1.3 Increasing Acceptance of the Contract Manufacturing Model
            5.1.4 Rising Healthcare Coverage Improving Drug Affordability
     5.2 Market Roadblocks
            5.2.1 Declining Population
            5.2.2 Drug Counterfeiting & Weak IPR Regime

6. Regulatory Environment

7. Competitive Analysis
     7.1 Sanofi-Aventis
     7.2 Novartis Pharma ZAO
     7.3 Roche Moscow Ltd.
     7.4 Farmstandart OAO
     7.5 Akrikhin OAO

Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.